WO2007123691A3 - Méthode de traitement de troubles de la coagulation sanguine - Google Patents

Méthode de traitement de troubles de la coagulation sanguine Download PDF

Info

Publication number
WO2007123691A3
WO2007123691A3 PCT/US2007/007924 US2007007924W WO2007123691A3 WO 2007123691 A3 WO2007123691 A3 WO 2007123691A3 US 2007007924 W US2007007924 W US 2007007924W WO 2007123691 A3 WO2007123691 A3 WO 2007123691A3
Authority
WO
WIPO (PCT)
Prior art keywords
blood coagulation
coagulation disorders
treating blood
lipidic particles
disorders
Prior art date
Application number
PCT/US2007/007924
Other languages
English (en)
Other versions
WO2007123691A2 (fr
Inventor
Sathy V Balu-Iyer
Robert M Straubinger
Razvan Michlea
Aaron Peng
Original Assignee
Univ New York State Res Found
Sathy V Balu-Iyer
Robert M Straubinger
Razvan Michlea
Aaron Peng
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York State Res Found, Sathy V Balu-Iyer, Robert M Straubinger, Razvan Michlea, Aaron Peng filed Critical Univ New York State Res Found
Publication of WO2007123691A2 publication Critical patent/WO2007123691A2/fr
Publication of WO2007123691A3 publication Critical patent/WO2007123691A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne une méthode de traitement de troubles de la coagulation sanguine. Cette méthode consiste à administrer à un individu des compositions renfermant des particules lipidiques comprenant la phospatidylcholine, le phosphatidylinositol et le cholestérol. Un ou plusieurs peptides, polypeptides ou protéines intervenant dans la cascade de la coagulation sanguine sont associés aux particules lipidiques.
PCT/US2007/007924 2006-03-30 2007-03-30 Méthode de traitement de troubles de la coagulation sanguine WO2007123691A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US78758606P 2006-03-30 2006-03-30
US78741106P 2006-03-30 2006-03-30
US60/787,411 2006-03-30
US60/787,586 2006-03-30
US86506206P 2006-11-09 2006-11-09
US60/865,062 2006-11-09

Publications (2)

Publication Number Publication Date
WO2007123691A2 WO2007123691A2 (fr) 2007-11-01
WO2007123691A3 true WO2007123691A3 (fr) 2008-05-29

Family

ID=38625470

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/007924 WO2007123691A2 (fr) 2006-03-30 2007-03-30 Méthode de traitement de troubles de la coagulation sanguine

Country Status (1)

Country Link
WO (1) WO2007123691A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2123258A1 (fr) * 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes pour l'administration de médicaments

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4920016A (en) * 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US5997864A (en) * 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4920016A (en) * 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US5997864A (en) * 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RAMANI K. ET AL.: "Passive Transfer of Polyethylene glycol to Liposomal-Recombinant Human FVIII Enhances its Efficacy in a Murine Model for Hemophilia A", J. PHARM. SCIENCES, February 2008 (2008-02-01), pages 1 - 12, XP008130854, DOI: doi:10.1002/JPS.21266 *
RAMANI K. ET AL.: "Phosphatidylserine Containing Liposomes Reduce Immunogenicity of Recombinant Human Factor VIII (rFVIII) in a Murine Model of Hemophilia A", J. PHARM. SCIENCES, vol. 97, April 2008 (2008-04-01), pages 1386 - 1398, XP008130853 *

Also Published As

Publication number Publication date
WO2007123691A2 (fr) 2007-11-01

Similar Documents

Publication Publication Date Title
WO2010065077A3 (fr) Antagonistes d'il-6 pour prévenir ou traiter la thrombose
PH12017502286A1 (en) Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
WO2007092772A8 (fr) Formulations de protéines
MX2010008206A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf.
WO2007091250A3 (fr) Enzymotherapie de remplacement pour le traitement des maladies lysosomiales
WO2009130198A3 (fr) Facteur ix de coagulation humain hyperglycosylé
WO2008127654A3 (fr) Procédés et compositions pour protéines de coagulation intra-articulaires
WO2007038459A3 (fr) Composes de carboxyamine et leurs methodes d'utilisation
WO2007149406A8 (fr) Polypeptides facteurs ix de la coagulation modifiés et leur utilisation thérapeutique
WO2007111866A3 (fr) Combinaisons d'un ou plusieurs inhibiteurs de la protéase du vhc et d'un ou plusieurs inhibiteurs de cyp3a4, et méthodes de traitement associées
IL222880A (en) Peptides and their use in the treatment and diagnosis of diseases and pharmaceutical preparations containing them
WO2006099610A3 (fr) Methodes d'identification de cibles therapeutiques pour le traitement de l'atrophie vulvovaginale
WO2007095288A3 (fr) Compositions protéiques ou peptidiques protéine contenant de la méthionine et leur procédé de fabrication et d'utilisation
WO2008076954A3 (fr) Composés hétérocycliques et procédés d'utilisation de ceux-ci
WO2009040420A3 (fr) Utilisation d'un monoterpène pour accroître une réparation tissulaire
WO2005112915A3 (fr) Diminution de l'etat de stress oxydatif par administration de produits naturels et de medicaments pharmaceutiques
WO2007111661A3 (fr) anticorps humains specifiques a des matieres et des procedes a base de gastrine
WO2008029169A3 (fr) Procédé de traitement de troubles respiratoires
WO2007056301A3 (fr) Thérapie avec un anticorps pour le traitement de maladies associées à l'intolérance au gluten
WO2006116410A3 (fr) Compositions et procedes destines a traiter ou a prevenir le surpoids ou l'obesite avec des fragments de proteines chargees en zinc
WO2006087393A3 (fr) Analogues structurels d'avenanthramides, leur utilisation dans des compositions servant au traitement de troubles dermatologiques
AU2003229284A1 (en) Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur
WO2008112325A3 (fr) Traitement de troubles auto-immuns
WO2007134118A3 (fr) Composition à base de protéines et méthodes d'utilisation
WO2006116185A3 (fr) Procedes destines au traitement de myelomes multiples

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07754443

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07754443

Country of ref document: EP

Kind code of ref document: A2